● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
REACT rilparencel Updated Oct 25
What to watch
The next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.
Bull case
- Phase 2 REGEN-007 Group 1 showed a 78% improvement in annual eGFR decline (4.6 mL/min/1.73m², p<0.001), with a subgroup matching Phase 3 criteria showing 85% improvement, per July 2025 top-line results.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation and agreed to an accelerated approval pathway using eGFR slope as a surrogate endpoint, potentially enabling approval from a single Phase 3 trial.
- PROACT 1 enrollment completed mid-2026 with topline results expected Q2 2027; cash of $181.6M (as of June 30, 2026) funds operations into mid-2027, covering the readout.
Bear case
- Phase 2 REGEN-007 was small (n=24 in the lead Group 1) and open-label; one of two dosing groups (Group 2) missed statistical significance, raising questions about robustness.
- Autologous cell therapy is complex and expensive to manufacture at scale since each dose is personalized from the patient's own kidney biopsy.
- Director Brian Pereira sold ~$715K worth of shares in August 2026 at ~$1.42, according to SEC Form 4 filings.